Amarna Therapeutics and TNO Announce SVac Research and Develment Partnershipop
News Jun 23, 2009
Dutch biotechnology company Amarna Therapeutics B.V. and the Netherlands Organization for Applied Scientific Research TNO have announced that they have entered into a collaboration agreement to further develop Amarna’s viral gene delivery platform SVac.
Under this agreement, TNO will develop novel methods for the manufacture, formulation and testing of viral gene delivery systems such as the SVac platform of Amarna. The collaboration is partly supported by a co-financing initiative aimed at developing innovative technologies.
“We are very pleased to work with TNO”, said Ben van Leent, CEO of Amarna Therapeutics. “We have developed a revolutionary novel viral gene delivery vector platform technology SVac for producing human therapeutics that have the potential to save lives and improve the quality of life for millions of people worldwide that are suffering from life-threatening or severe chronic diseases. The technology is now available to address the major diseases of our time including genetic disorders, autoimmune diseases, allergies and cancer. Amarna Therapeutics acts at the forefront of the therapeutic vaccination and gene therapy markets. Both markets are rapidly growing to reach an estimated 40 billion Euro’s in 2015. I’m convinced that the therapeutics in our pipeline all have blockbuster potential. The partnership with TNO enables us to initiate the first time in man clinical trials with one of our lead therapeutics in 2010.”
“The partnership between TNO and Amarna allows us to expand our pre-clinical development services into the extremely important therapeutic area of viral vector and gene delivery technologies and is yet another important step in our establishment of a fully integrated and highly innovative package of biopharmaceutical development capabilities” says Menzo Havenga, Managing Director of Biosciences at TNO.
Habitat loss, habitat fragmentation and the loss of genetic diversity are the main factors driving the extinction of many wild species, and the few eastern massasauga rattlesnakes remaining in Illinois have certainly suffered two of the three. A long-term study of these snakes reveals, however, that – despite their alarming decline in numbers – they have retained a surprising amount of genetic diversity.READ MORE
Researchers have discovered a navigational gene in glass catfish called the electromagnetic-perceptive gene, or EPG, that responds to certain magnetic waves. These findings have the potential to revolutionize treatments for humans and help those who suffer from tremors related to Parkinson’s and seizures associated with epilepsy.